286 related articles for article (PubMed ID: 30226786)
21. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
22. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
23. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
Gandhi NM; Morales A; Lamm DL
BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
[TBL] [Abstract][Full Text] [Related]
24. Adjuvants for cancer vaccines.
Dubensky TW; Reed SG
Semin Immunol; 2010 Jun; 22(3):155-61. PubMed ID: 20488726
[TBL] [Abstract][Full Text] [Related]
25. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.
Gableh F; Saeidi M; Hemati S; Hamdi K; Soleimanjahi H; Gorji A; Ghaemi A
J Biomed Sci; 2016 Jan; 23():16. PubMed ID: 26811064
[TBL] [Abstract][Full Text] [Related]
26. Challenges of using lipopolysaccharides for cancer immunotherapy and potential delivery-based solutions thereto.
Shetab Boushehri MA; Lamprecht A
Ther Deliv; 2019 Mar; 10(3):165-187. PubMed ID: 30909855
[TBL] [Abstract][Full Text] [Related]
27. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
[TBL] [Abstract][Full Text] [Related]
28. The effects of administration of ligands for Toll-like receptor 4 and 21 against Marek's disease in chickens.
Parvizi P; Abdul-Careem MF; Mallick AI; Haq K; Haghighi HR; Orouji S; Heidari M; Behboudi S; Sharif S
Vaccine; 2014 Apr; 32(17):1932-8. PubMed ID: 24530927
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
Rostamian M; Niknam HM
Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
[TBL] [Abstract][Full Text] [Related]
30. Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants.
Strobl S; Hofbauer K; Heine H; Zamyatina A
Chemistry; 2022 Jun; 28(35):e202200547. PubMed ID: 35439332
[TBL] [Abstract][Full Text] [Related]
31. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants.
Fox CB; Friede M; Reed SG; Ireton GC
Subcell Biochem; 2010; 53():303-21. PubMed ID: 20593273
[TBL] [Abstract][Full Text] [Related]
32. Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses.
Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Dolzhikova IV; Stanhope-Baker P; Naroditsky BS; Gudkov AV; Logunov DY; Gintsburg AL
PLoS One; 2016; 11(5):e0155650. PubMed ID: 27187797
[TBL] [Abstract][Full Text] [Related]
33. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
34. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story.
Herr HW; Morales A
J Urol; 2008 Jan; 179(1):53-6. PubMed ID: 17997439
[TBL] [Abstract][Full Text] [Related]
35. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
Smits EL; Ponsaerts P; Berneman ZN; Van Tendeloo VF
Oncologist; 2008 Aug; 13(8):859-75. PubMed ID: 18701762
[TBL] [Abstract][Full Text] [Related]
36. Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.
Baxevanis CN; Voutsas IF; Tsitsilonis OE
Immunotherapy; 2013 May; 5(5):497-511. PubMed ID: 23638745
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Gene Expression by Sheep and Human Blood Stimulated with the TLR4 Agonists Lipopolysaccharide and Monophosphoryl Lipid A.
Enkhbaatar P; Nelson C; Salsbury JR; Carmical JR; Torres KE; Herndon D; Prough DS; Luan L; Sherwood ER
PLoS One; 2015; 10(12):e0144345. PubMed ID: 26640957
[TBL] [Abstract][Full Text] [Related]
38. Mycobacterium leprae Activates Toll-Like Receptor-4 Signaling and Expression on Macrophages Depending on Previous Bacillus Calmette-Guerin Vaccination.
Polycarpou A; Holland MJ; Karageorgiou I; Eddaoudi A; Walker SL; Willcocks S; Lockwood DN
Front Cell Infect Microbiol; 2016; 6():72. PubMed ID: 27458573
[TBL] [Abstract][Full Text] [Related]
39. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy.
Venezia S; Refolo V; Polissidis A; Stefanis L; Wenning GK; Stefanova N
Mol Neurodegener; 2017 Jul; 12(1):52. PubMed ID: 28676095
[TBL] [Abstract][Full Text] [Related]
40. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.
Beatty GL; Li Y; Long KB
Expert Rev Anticancer Ther; 2017 Feb; 17(2):175-186. PubMed ID: 27927088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
